Conoidin A Abrogates Growth of Anchorage-Dependent and Anchorage-Independent SKOV3 Ovarian Cancer Cells

Kalyn M. Borger, Kassidy M. Jungles, Marissa Powell, Marianna Sanchez,Calli A. Davison-Versagli

Reactive Oxygen Species(2022)

Cited 0|Views2
No score
Abstract
Ovarian cancer is one of the leading causes of cancer death in the United States with only 49% of women surviving 5 years after initial diagnosis. Poor screening methods, chemoresistance, and its high metastatic capacity make this disease difficult to treat. Thus, improved treatment methodologies are necessary to improve survival rates and quality of life for ovarian cancer patients. Conoidin A is a water-soluble covalent inhibitor of peroxiredoxin 1 (PRDX1) and peroxiredoxin 2 (PRDX2). While its effects have been primarily studied on parasites, recent studies also begin to elucidate the impacts of conoidin A in other human health conditions, including anticancer effects. However, the anticancer effects and potential utility of conoidin A as a therapeutic, specifically in ovarian cancer, has yet to be investigated. Here, we report that conoidin A eliminates growth of anchorage-dependent and anchorage-independent SKOV3 cells. Furthermore, analyses of clinical samples show increased expression of PRDX1 and PRDX2 in ovarian cancerous tissue, which are the targets of conoidin A. These data identify conoidin A as a potential therapeutic for early and late-stage ovarian cancer and warrants further investigation. (First Online: December 31, 2022)
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined